Cargando…

Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer

BACKGROUND: Only a fraction of patients with advanced non-small cell lung cancer (NSCLC) respond well to immune checkpoint blockade (ICB) therapy. Here, we investigated whether Titin (TTN) mutation, which has been demonstrated to be a predictive biomarker in tissue-based analysis, can identify patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Chunxia, Wang, Xinxin, Zhou, Juan, Zhao, Jing, Zhou, Fei, Zhao, Guodong, Xu, Xiaohong, Zou, Xuan, Zhu, Bo, Jia, Qingzhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044474/ https://www.ncbi.nlm.nih.gov/pubmed/33889507 http://dx.doi.org/10.21037/tlcr-20-1118

Ejemplares similares

Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer
por: Zhou, Juan, et al.
Publicado: (2021)

The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Ren, Sijia, et al.
Publicado: (2021)

Adverse impact of bone metastases on clinical outcomes of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors
por: Li, Xing, et al.
Publicado: (2020)

Increasing Role of Titin Mutations in Neuromuscular Disorders
por: Savarese, Marco, et al.
Publicado: (2016)

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer
por: Yu, Xin, et al.
Publicado: (2021)

Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
por: Qiao, Meng, et al.
Publicado: (2021)

Chromothripsis is correlated with reduced cytotoxic immune infiltration and diminished responsiveness to checkpoint blockade immunotherapy
por: Chu, Han, et al.
Publicado: (2023)

Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer
por: Jia, Qingzhu, et al.
Publicado: (2020)

Flight of the titins
por: Dove, Alan W.
Publicado: (2001)

Clash of the titin
por: LeBrasseur, Nicole
Publicado: (2002)

Contributions of Titin and Collagen to Passive Stress in Muscles from mdm Mice with a Small Deletion in Titin’s Molecular Spring
por: Hettige, Pabodha, et al.
Publicado: (2022)

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer
por: Zhou, Huaqiang, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
por: Wang, Haowei, et al.
Publicado: (2023)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
por: Metro, Giulio, et al.
Publicado: (2021)

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer
por: Li, Song, et al.
Publicado: (2023)

Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
por: Sun, Shangqin, et al.
Publicado: (2021)

A titinic extension
por: Wells, William A.
Publicado: (2002)

Of cilia, titin, and neurosteroids
por: Adler, Elizabeth M.
Publicado: (2014)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: Jacquelot, N., et al.
Publicado: (2017)

Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy
por: Cremolini, Chiara, et al.
Publicado: (2021)

Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma
por: Xie, Xiaona, et al.
Publicado: (2021)

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
por: Ravi, Arvind, et al.
Publicado: (2023)

Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data
por: Song, Zhuo, et al.
Publicado: (2022)

Neoantigen Tracking: Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer (Adv. Sci. 9/2020)
por: Jia, Qingzhu, et al.
Publicado: (2020)

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
por: Hastings, K, et al.
Publicado: (2019)

Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype
por: Hao, Xue, et al.
Publicado: (2020)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
por: Wilkinson, Robert W., et al.
Publicado: (2018)

Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology
por: Liu, Zefan, et al.
Publicado: (2022)

A new spring for titin
por: Brunello, Elisabetta, et al.
Publicado: (2020)

The Mechanical Power of Titin Folding
por: Eckels, Edward C., et al.
Publicado: (2019)

Acquired Resistance to Immune Checkpoint Blockade Therapies
por: Zhao, Xianda, et al.
Publicado: (2020)

Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer
por: Cui, Yu, et al.
Publicado: (2023)

An advanced non-small cell lung cancer patient with epidermal growth factor receptor sensitizing mutation responded to toripalimab in combination with chemotherapy after resistance to osimertinib: a case report
por: Zhou, Juan, et al.
Publicado: (2020)

Phosphorylation of Titin Modulates Passive Stiffness of Cardiac Muscle in a Titin Isoform-dependent Manner
por: Fukuda, Norio, et al.
Publicado: (2005)

Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Xie, Mengqing, et al.
Publicado: (2021)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases
por: Zhou, Juan, et al.
Publicado: (2020)

Cancer Mutational Load: The More the Merrier for Immune Checkpoint Blockade Therapies
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0e99dktobhivqofbtnjn172htf